PET/CT for patients with breast cancer: where is the clinical impact?
GA Ulaner - American Journal of Roentgenology, 2019 - Am Roentgen Ray Soc
OBJECTIVE. FDG PET/CT affects the management of patients with breast cancer in multiple
settings, including initial staging, treatment response assessment, and evaluation of …
settings, including initial staging, treatment response assessment, and evaluation of …
PET/CT for Patients With Breast Cancer: Where Is the Clinical Impact?
GA Ulaner - AJR. American Journal of Roentgenology, 2019 - europepmc.org
OBJECTIVE. FDG PET/CT affects the management of patients with breast cancer in multiple
settings, including initial staging, treatment response assessment, and evaluation of …
settings, including initial staging, treatment response assessment, and evaluation of …
[引用][C] PET/CT for Patients With Breast Cancer: Where Is the Clinical Impact?
GA Ulaner - American Journal of Roentgenology, 2019 - cir.nii.ac.jp
PET/CT for Patients With Breast Cancer: Where Is the Clinical Impact? | CiNii Research CiNii
国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
PET/CT for Patients With Breast Cancer: Where Is the Clinical Impact?
GA Ulaner - AJR. American journal of roentgenology, 2019 - pubmed.ncbi.nlm.nih.gov
OBJECTIVE. FDG PET/CT affects the management of patients with breast cancer in multiple
settings, including initial staging, treatment response assessment, and evaluation of …
settings, including initial staging, treatment response assessment, and evaluation of …